Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONS-5010 (bevacizumab) vs ranibizumab in wet AMD
NCT03844074Phase 3Completed
- Sponsor
- Outlook Therapeutics
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in exudative macular degeneration (2 arms), sponsored by Outlook Therapeutics. Primary endpoint: Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score at 11 months. Started Oct 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03844074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844074.